HHV-8 Antibody (LN35): sc-57808

HHV-8 Antibody (LN35) is a rat monoclonal IgG2c antibody that detects HHV-8 in non-species reactive applications such as immunofluorescence (IF) and immunohistochemistry with paraffin-embedded sections (IHCP). HHV-8 (LN35) antibody is available in a non-conjugated form, providing researchers with a versatile tool for studying the Kaposi′s sarcoma-associated herpesvirus, which is linked to serious conditions like multicentric Castleman′s disease and primary effusion lymphoma, a rare non-Hodgkin lymphoma affecting body cavities. HHV-8 protein K14 plays a crucial role during the lytic cycle, as K14 is expressed on the surfaces of infected cells and interacts with human CD200R, a receptor found on myeloid cells that helps regulate macrophage activation. This interaction is significant because K14 inhibits tumor necrosis factor alpha (TNFα) production, thereby locally restraining macrophage activation and potentially contributing to the virus′s ability to evade the host immune response. Additionally, HHV-8 encodes a viral cyclin that is homologous to cellular D-type cyclins, which are essential for cell cycle progression. Unlike cellular counterparts, HHV-8 cyclins are not regulated by the p27 cell cycle inhibitor, which may elucidate the high proliferative index observed in individuals with primary effusion lymphoma, where both p27 and high levels of viral cyclin coexist. This unique characteristic of HHV-8 cyclin underscores the importance of understanding the molecular interactions and regulatory mechanisms involved in viral pathogenesis, making anti-HHV-8 antibody (LN35) an invaluable resource for researchers investigating these complex processes.